Browsing by Subject "placental growth factor"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV
    (Elsevier, 2017-12) Conroy, Andrea L.; McDonald, Chloe R.; Gamble, Joel L.; Olwoch, Peter; Natureeba, Paul; Cohan, Deborah; Kamya, Moses R.; Havlir, Diane V.; Dorsey, Grant; Kain, Kevin C.; Pediatrics, School of Medicine
    Background Angiogenic processes in the placenta are critical regulators of fetal growth and impact birth outcomes, but there are limited data documenting these processes in HIV-infected women or women from low-resource settings. Objective We sought to determine whether angiogenic factors are associated with adverse birth outcomes in HIV-infected pregnant women started on antiretroviral therapy. Study Design This is a secondary analysis of samples collected as part of a clinical trial randomizing pregnant women and adolescents infected with HIV to lopinavir/ritonavir-based (n = 166) or efavirenz-based (n = 160) antiretroviral therapy in Tororo, Uganda. Pregnant women living with HIV were enrolled between 12-28 weeks of gestation. Plasma samples were evaluated for angiogenic biomarkers (angiopoietin-1, angiopoietin-2, vascular endothelial growth factor, soluble fms-like tyrosine kinase-1, placental growth factor, and soluble endoglin) by enzyme-linked immunosorbent assay between: 16-<20, 20-<24, 24-<28, 28-<32, 32-<36, 36-<37 weeks of gestation. The primary outcome was preterm birth. Results In all, 1115 plasma samples from 326 pregnant women and adolescents were evaluated. There were no differences in angiogenic factors according to antiretroviral therapy group (P > .05 for all). The incidence of adverse birth outcomes was 16.9% for spontaneous preterm births, 25.6% for small-for-gestational-age births, and 2.8% for stillbirth. We used linear mixed effect modelling to evaluate longitudinal changes in angiogenic factor concentrations between birth outcome groups adjusting for gestational age at venipuncture, maternal age, body mass index, gravidity, and the interaction between treatment arm and gestational age. Two angiogenic factors–soluble endoglin and placental growth factor–were associated with adverse birth outcomes. Significantly higher concentrations of soluble endoglin throughout gestation were found in study participants destined to deliver preterm [likelihood ratio test, χ2(1) = 12.28, P < .0005] and in those destined to have stillbirths [χ2(1) = 5.67, P < .02]. By contrast, significantly lower concentrations of placental growth factor throughout gestation were found in those destined to have small-for-gestational-age births [χ2(1) = 7.89, P < .005] and in those destined to have stillbirths [χ2(1) = 21.59, P < .0001]. Conclusion An antiangiogenic state in the second or third trimester is associated with adverse birth outcomes, including stillbirth in women and adolescents living with HIV and receiving antiretroviral therapy.
  • Thumbnail Image
    Item
    Placental protein levels in maternal serum are associated with adverse pregnancy outcomes in nulliparous patients
    (ScienceDirect, 2022) Parry, Samuel; Carper, Benjamin A.; Grobman, William A.; Wapner, Ronald J.; Chung, Judith H.; Haas, David M.; Mercer, Brian; Silver, Robert M.; Simhan, Hyagriv N.; Saade, George R.; Reddy, Uma M.; Parker, Corette B.; Obstetrics and Gynocology, School of Medicine
    Background The NICHD Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (nuMoM2b) was established to investigate the underlying causes and pathophysiologic pathways associated with adverse pregnancy outcomes in nulliparous gravidas. Objective Our objectives were to study placental physiology and identify novel biomarkers in relation to adverse pregnancy outcomes, including preterm birth (medically-indicated and spontaneous), preeclampsia, small for gestational age (SGA) neonates, and stillbirth. We measured levels of placental proteins in the maternal circulation in the first two trimesters of pregnancy. Materials and Methods Maternal serum samples were collected at two study visits (6-13 weeks and 16-21 weeks), and levels of nine analytes were measured. The analytes we measured were vascular endothelial growth factor (VEGF), placental growth factor (PlGF), endoglin (Eng), soluble fms-like tyrosine kinase-1 (sFlt-1), A disintegrin and metalloproteinase domain-containing protein 12 (ADAM12), pregnancy-associated plasma protein A (PAPP-A), free β human chorionic gonadotropin (βhCG), inhibin A, and alpha-fetoprotein (AFP). The primary outcome was preterm birth between 20 weeks 0 days and 36 weeks 6 days gestation. Secondary outcomes were spontaneous preterm births, medically-indicated preterm births, preeclampsia, SGA neonates, and stillbirth. Results A total of 10,038 eligible gravidas were enrolled into the nuMoM2b cohort, from which a nested case-control study was performed comparing 800 cases with preterm birth (466 spontaneous preterm births, 330 medically-indicated preterm births, and 4 unclassified preterm births), 568 with preeclampsia, 406 with SGA birth, and 49 with stillbirth, with 911 controls who delivered at term without complications. Although levels of each analyte generally differed between cases and controls at one or both visits, the odds ratios revealed a less than two-fold difference between cases and controls in all comparisons. Receiver operating characteristic curves, generated to determine the relationship between analyte levels and preterm birth and the other adverse pregnancy outcomes, resulted in areas under the curves (AUCs) that were relatively low (range 0.50-0.64) for each analyte. Logistic regression modeling demonstrated that AUCs for predicting adverse pregnancy outcomes were greater using baseline clinical characteristics and combinations of analytes compared to baseline characteristics alone, but AUCs remained relatively low for each outcome (0.65-0.78). Conclusion We have found significant associations between maternal serum levels of analytes evaluated early in pregnancy and subsequent adverse pregnancy outcomes in nulliparous gravidas. However, the test characteristics for these analytes do not support their use as clinical biomarkers to predict adverse pregnancy outcomes, either alone or in combination with maternal clinical characteristics.